BLUDIGO
Peakindigotindisulfonate sodium
NDAINTRAVENOUSSOLUTION
Approved
Jul 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
BLUDIGO (indigotindisulfonate sodium) is 12. First approved in 2022.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLUDIGO (indigotindisulfonate sodium) is an intravenous diagnostic dye that enhances visualization of ureteral orifices during urological procedures by producing a deep blue color. The dye is renally excreted via tubular secretion and becomes detectable at target sites within 4–9 minutes of IV injection. It is indicated for use in cystoscopic procedures to aid in identification of ureteral anatomy.
Peak11.6 years to LOE
Product is in peak lifecycle phase with no direct competitors, positioning the brand team to focus on market penetration and procedure adoption in urology centers.
Mechanism of Action
12.1 Mechanism of Action Indigotindisulfonate is a dye excreted by the kidney through tubular secretion and enhances visualization of the ureteral orifices by its deep blue color. 12.2 Pharmacodynamics The blue color is detectable at the ureteral orifices within 4 minutes to 9 minutes after the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BLUDIGO offers a unique opportunity to establish market presence in a monopoly-like diagnostic niche with strong patent protection through 2037. The lack of current job postings suggests the product may be early in its commercial build-out, making it an attractive entry point for professionals seeking to shape market strategy in a specialty urology segment.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.